Coya Therapeutics, Inc. (NASDAQ: COYA) is a Healthcare company (Biotechnology) with a market capitalization of $71M. The Maz Rating grades it against the other companies in its sector.
Coya Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $3.02, Coya Therapeutics, Inc. trades at 14.9x sales and 2.1x book value. Over the last twelve months it generated about $5M of revenue and a net loss of $33M. It runs an operating margin of -675.3% and a net margin of -643.5%. It shows return on equity of -71.5%, return on invested capital of -93.3% and a free cash flow yield of -29.8%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 7.24. Over the past 52 weeks the share price ranged from $2.72 to $6.62, with a beta of 0.58.
Coya Therapeutics, Inc. does not currently pay a dividend.
6 Wall Street analyst ratings cover the stock: 6 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.